T A B L E O F C O N T E N T S

Authors' conclusions
There is no evidence from randomised trials to support current guidance and practice. Guidance and practice are based on expert consensus, clinical experience and good intentions rather than high quality evidence.
Note: the 61 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
P L A I N L A N G U A G E S U M M A R Y
Physical health care monitoring for people with serious mental illness
In recent years there has been an increasing focus on the physical health of people who suffer from mental illness, it has been recognised that these individuals are at greater risk of physical health problems for a variety of reasons. There are now a number of different guidelines telling us how we should monitor physical health in this population. We searched for randomised trials that looked at the effectiveness of physical health monitoring in preventing deterioration of physical health and maintaining quality of life. Despite the amount of guidance available we found no relevant studies. Consequently there is no evidence from randomised controlled trials that physical health monitoring in people with severe mental illness is useful in preventing deterioration in physical health and maintaining quality of life. This, however, does not mean that physical health monitoring does not affect the physical health of people with severe mental illness.
B A C K G R O U N D
Description of the condition
The definition of severe mental illness with the widest consensus is that of the National Institute of Mental Health (NIMH) (Schinnar 1990) and is based on diagnosis, duration and disability (NIMH 1987) . People with serious mental illness have conditions such as schizophrenia or bipolar disorder, over a protracted period of time resulting in erosion of functioning in day to day life. A European survey put the total population-based annual prevalence of serious mental illness at approximately two per thousand (Ruggeri 2000) . As a consequence of their illness people with serious mental illness have a significantly reduced life expectancy for a variety of reasons including: poor self care, adverse health behaviours (smoking, sedentary lifestyle) and negative effects from psychotropic medication (weight gain, metabolic syndrome) (Robson 2007) . In schizophrenia, for example, life expectancy is reduced by around ten years (Newman 1991) . A recent publication has shown that people with schizophrenia have a threefold increase in mortality compared with the general population of England and Wales, and that approximately 81% of that increase is from natural causes, especially cardiovascular disease (Brown 2010) . There is historical evidence that sufferers from serious mental illness also have increased rates of infectious diseases (including HIV) (Cournos 2005) , non-insulin dependent diabetes, respiratory disease and cancer (Dixon 1999 , Robson 2007 . Despite this, evidence says that there exists a lack of physical health monitoring in people with serious mental illness in both the primary care (Burns 1998) and in the secondary care setting (Paton 2004) .
Description of the intervention
Physical health monitoring can take many forms, and these forms are highly divergent and dependent on environmental and socioeconomic factors. In some instances monitoring is indicated for a specific group of people because of demographic risk factors; one such population are those suffering from serious mental illness (Robson 2007) . People with illnesses such as schizophrenia are at greater risk for a number of conditions. This is compounded by the fact that they are less likely to seek medical advice and more likely to be exposed to medications with potentially negative health consequences (Weinmann 2009). People with serious mental illnesses should stand to benefit greatly from a programme of well organised and regular physical health monitoring. Monitoring differs from promotion in that its principle aim is to obtain information which can then be acted on to treat or prevent a physical health problem. Promotion, on the other hand, is the provision of information and encouragement to people in the hope that they will act to avoid deterioration of current health or development of future health problems. The effects of physical health promotion/advice for people with serious mental illness is evaluated in another future review in this series: Physical health advice for people with serious mental illness. Past reviewers have suggested that "essential routine health monitoring [for people with serious mental illness] should include weight, body mass index (BMI) and waist circumference, blood pressure, lipid profiles, screening for insulin resistance and diabetes, dental checks and eye health checks" (Robson 2007) . Physical health care monitoring could, therefore, range from the simplest forms of selfmonitoring, through to more systematised self-screening, to wellregulated and guideline-directed monitoring of health by health care professionals.
How the intervention might work
Information obtained from physical health monitoring is often the catalyst for more intensive medical input which can be either curative, palliative or preventative. The routine employment of simple and relatively inexpensive physical health monitoring has the potential to identify current, and pre-empt future, health problems. Subsequent action could improve the quality and duration of life for sufferers of serious mental illness. Additional benefits may include a reduction in dependence on medical services. "There are potential savings to be made on prescribing and acute care budgets through prevention or early detection of serious illness in these groups of service users" (DoH 2006) .
Why it is important to do this review
In August 2006 the UK's Department of Heath published a commissioning framework (DoH 2006) which, based on examples of current practice (including pilot programmes and expert advice), was intended to provide best practice guidance on the physical health needs of people with severe mental illness. In conjunction with this publication there has been significant investment in 88 English Primary Care Trusts known as 'Spearhead' Trusts to implement the services it suggested. In addition, a raft of guidance around physical heath monitoring in psychiatry has arisen over recent years from organisations such as the Royal College of Psychiatrists (RCPsych 2009; RCPsych 2009a) , the National Institute for Clinical Excellence (NICE 2006 ), Maudsley Prescribing Guidelines (Taylor 2009 and the Serious Mental Illness Physical Health Improvement Profile (White 2009). At no point does the current commissioning framework or guidance documents refer to evidence from randomised control trials or previous reviews. This pathway of identifying a problem, consultation, creation of guidelines and investment to implement the guidance would appear to make good sense. We feel that, at this point, it would be good to assess available evidence of the effects of physical health monitoring.
O B J E C T I V E S
Primary objective
To investigate the effects of the implementation of specific physical healthcare monitoring compared with standard care in a population suffering from severe mental illness.
Secondary objective
To compare types and techniques of monitoring.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials, and economic evaluations conducted alongside included randomised controlled trials. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week. When we encountered trials described in some way as to suggest or imply that the study was randomised and where the demographic details of each group's participants were similar, we included them and a sensitivity analysis was undertaken to the presence or absence of these data.
Types of participants
We required that a majority of participants should be within the age range 18 to 65 years and suffering from severe mental disorder preferably as defined by National Institute of Mental Health (NIMH 1987) but in the absence of that, from diagnosed illness such as schizophrenia, schizophrenia-like disorders, bipolar disorder, or serious affective disorders. We did not consider substance abuse to be a severe mental disorder in its own right, however we did feel that studies should remain eligible if they dealt with people with dual diagnoses, that is those with severe mental illness plus substance abuse. We did not include studies focusing on dementia, personality disorder and mental retardation as they are not covered by our definition of severe mental disorder.
Types of interventions
1. Physical health care monitoring 1.1 General physical health care monitoring in addition to standard care: monitoring can be any means of observation, supervision, keeping under review or measuring or testing at intervals. We defined 'physical health' as 'soundness of body' as opposed to the world health organisation's definition of 'health' which includes mental and social well being (WHO 1948).
1.2 Focused physical health care monitoring: adherent to specific guidance e.g. as a result of an identified illness (blood sugar in diabetes) or as a result of pharmacological treatment (weight gain with atypical antipsychotic), in addition to standard care. 2. Standard care Care in which physical health monitoring is not specifically emphasised above and beyond care that would be expected for people not suffering from severe mental illness.
Variations in delivery
We feel that there may be important studies comparing different types of monitoring delivered in several ways. We are interested in these studies and will endeavour to include them in a relevant comparison. 3.1 Differences in who undertakes the monitoring -self monitoring vs monitoring by health care professional. 3.2 Differences in complexity of monitoring -simple routine check/test vs complex check/test. 3.3 Differences in focus of checks -specific health check vs nonspecific health check. 3.4 Differences in pattern of checking -once only checks vs regular checks. 3.5 Differences in guidance followed -one set of guidelines vs another.
Types of outcome measures
For the purposes of this review outcomes we divided outcomes into four time periods, i. immediate (within one week) ii. short term (one week to six months) iii. medium term (six months to one year) and, iv. long term (over one year). 
Search methods for identification of studies
Electronic searches 1. Cochrane Schizophrenia Group Trials Register (October 2009) The register was searched using the phrase:[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* or *advice* or *monitor* in title of REFERENCES) AND (*education* OR *health promot* OR *preventi* OR *motivate* or *advice* or *monitor* in interventions of STUDY)] The Cochrane Schizophrenia Group's Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see Group Module). Incoming trials are assigned to relevant existing or new review titles. 2. The Trials Search Co-ordinator, Samantha Roberts, searched the Cochrane Schizophrenia Group Trials Register register (October 2012) using the phrase: [(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* or *advice* or *monitor* in title of REFERENCES) AND (*education* OR *health promot* OR *preventi* OR *motivate* or *advice* or *monitor* in interventions of STUDY)] The Cochrane Schizophrenia Group's Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see Group Module). Incoming trials are assigned to relevant existing or new review titles.
Searching other resources 1.Unsystematic Search
We undertook unsystematic searches of a sample of the component databases (BNI, CINHAL, EMBASE, MEDLINE and Psych-INFO) to determine if any material may have been overlooked. We searched using specific phrases ('physical health', 'monitoring' and 'mental illness') as the searches that create the Cochrane Schizophrenia Group's register of trials are methodology specific. We did not identify any relevant trials.
Reference Searching
We inspected the references of all identified studies for other relevant studies.
Personal Contact
We contacted the first author of each included for information regarding unpublished trials.
Data collection and analysis
Selection of studies
Authors GT, AC and SM screened the results of the electronic search. MB inspected a random sample of these results, comprising 10% of the total. The principal reviewer GT and co-reviewer AC inspected all abstracts of studies identified through screening and identified potentially relevant reports. Where disagreement occurred we resolved this by discussion, and where there was still doubt, we acquired the full article for further inspection. We then requested the full articles of relevant reports for reassessment and carefully inspected them for a final decision on inclusion (see Criteria for considering studies for this review). In turn GT and AC inspected all full reports and independently decided whether they met inclusion criteria. We were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked author MB for help and if it was impossible to decide, these studies were added to those awaiting assessment and the authors of the papers contacted for clarification.
Data extraction and management
1. Extraction Authors GT and AC independently extracted data from included studies. Again, we discussed any disagreement, documented our decisions and, if necessary, we contacted the authors of studies for clarification. With remaining problems MB helped clarify issues and we documented our final decisions. We extracted data presented only in graphs and figures whenever possible, we only included it if two reviewers independently had the same result. We made attempts to contact authors through an open-ended request in order to obtain any missing information or for clarification whenever necessary. Where possible, we extracted data relevant to each component centre of multi-centre studies separately. 2. Management 2.1 Forms GT and AC extracted data onto standard, simple forms. 2.2 Data from multi-centre trials Where possible the authors verified independently calculated centre data against original trial reports. 3. Scale-derived data We included continuous data from rating scales only if: a. the psychometric properties of the measuring instrument had been described in a peer-reviewed journal (Marshall 2000); and b. the measuring instrument was not written or modified by one of the trialists for that particular trial; and c. the measuring instrument is either i. a self-report or ii. completed by an independent rater or relative (not the therapist).
Endpoint versus change data
We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view. Change data are often not ordinal and are very problematic to interpret. If endpoint data were unavailable, we used change data.
Skewed data
Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aim to apply the following standards to all data before inclusion: (a) standard deviations and means are reported in the paper or obtainable from the authors; (b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (Altman 1996); (c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above will be modified to take the scale starting point into account. In these cases skew is present if 2SD>(S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We entered skewed data from studies of less than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large, and we entered skewed data from large sample sizes into syntheses. 6. Common measure To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital, (mean days per year, per week or per month) to a common metric (e.g. mean days per month). 7. Conversion of continuous to binary Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the Positive and Negative Syndrome Scale (Kay 1986 , Kay 1987 , this could be considered as a clinically significant response (Leucht 2005 , Leucht 2005a ). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors. 8. Direction of graphs Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for physical health monitoring. 9. Summary of findings 
Assessment of risk of bias in included studies
Again working independently, GT,AC and MB assessed risk of bias using the tool described in the Cochrane Collaboration Handbook (Higgins 2008). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would have excluded studies where allocation was clearly not concealed. We did not include trials with high risk of bias (defined as at least 3 out of 5 domains were categorised as 'No') in the meta-analysis. If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials are provided, we contacted the authors of the studies in order to obtain further information. Non-concurrence in quality assessment was reported.
Measures of treatment effect
1. Binary data For binary outcomes we calculated a standard estimation of the random-effect risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (Boissel 1999) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (Deeks 2000) . Within the Summary of Findings table we assumed for calculation of the low risk groups that the lowest control risk applied to all data. We did the same for the assumption of the highest risk groups. We used the Summary of Findings table to calculate absolute risk reduction for primary outcomes. 2. Continuous data 2.1 Summary statistic For continuous outcomes we estimated a fixed-effect mean difference between groups. We preferred not to calculate effect size measures (standardised mean difference SMD). However, in the case of where scales were of such similarity to allow presuming there was a small difference in measurement, we calculated it and, whenever possible, we transformed the effect back to the units of one or more of the specific instruments.
Unit of analysis issues
1. Cluster trials Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997 , Gulliford 1999 . Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra class correlation co-efficient of their clustered data and to adjust for this by using accepted methods (Gulliford 1999) . Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted for the clustering effect. We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra class correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999). If cluster studies has been appropriately analysed taking into account intra class correlation co-efficient and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. 2. Cross-over trials A major concern of cross-over trials is the carryover effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies. 3. Studies with multiple treatment groups Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. Where the additional treatment arms were not relevant, we did not reproduce these data.
Dealing with missing data
Overall loss of credibility
At some degree of loss of follow up data must lose credibility (Xia 2009). For any particular outcome should than 50% of data be unaccounted, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with '*' to indicate that such a result may well be prone to bias.
Binary
In the case where attrition for a binary outcome is between 0 and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention to treat analysis). Those lost to follow up were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death. A sensitivity analysis was undertaken testing how prone the primary outcomes were to change when 'completed' data only were compared to the intention to treat analysis using the above assumption.
Continuous 3.1 Attrition
In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we have reproduced these.
Standard deviations
Where there are missing measures of variance for continuous data but exact standard error and confidence interval are available for group means , either 'p' value or 't' value are available for differences in mean, we calculated standard deviation value according to method described in Section 7.7.3 of the Cochrane Handbook (Higgins 2008). If standard deviations were not reported and could not be calculated from available data, we asked authors to supply the data. In the absence of data from authors, the mean standard deviation from other studies was used.
Last observation carried forward
We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results. Therefore, where LOCF data has been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions.
Assessment of heterogeneity
Clinical heterogeneity
To judge clinical heterogeneity, we considered all included studies, initially without seeing comparison data. We simply inspected all studies for clearly outlying situations or people which we had not predicted would arise. Should such situations or participant groups arise these will be fully discussed.
Methodological heterogeneity
We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. Should such methodological outliers arise these will be fully discussed. 3. Statistical
Visual inspection
We visually inspected graphs to investigate the possibility of statistical heterogeneity. 3.2 Employing the I-squared statistic Heterogeneity between studies was investigated by considering the I-squared method alongside the Chi 2 'p' value. The I 2 provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003) . The importance of the observed value of I 2 depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'p' value from Chi 2 test, or a confidence interval for I 2 ). I 2 estimate greater than or equal to 50% accompanied by a statistically significant Chi 2 statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 -Higgins 2008) and reasons for heterogeneity were explored. If the inconsistency was high and the clear reasons were found, we presented data separately.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These are described in Section 10 of the Cochrane Handbook (Higgins 2008). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.
Data synthesis
Where possible we employed a random-effect model for analyses. We understand that there is no closed argument for preference for use of fixed or random-effect models. The random-effect method incorporates an assumption that different studies are estimating different, yet related, intervention effects. According to our hypothesis of an existing variation across studies, to be explored further in the meta-regression analysis despite being cautious that that random-effects methods does put added weight onto the smaller of the studies -we favoured using random-effect model.
Subgroup analysis and investigation of heterogeneity 1. Subgroup analyses
We anticipate no sub-group analyses. 2. Investigation of heterogeneity 2.1 Unanticipated heterogeneity Should unanticipated clinical or methodological heterogeneity be obvious we will simply state hypotheses regarding these for future reviews or versions of this review. We do not anticipate undertaking analyses relating to these.
Anticipated heterogeneity
We are concerned that focused physical health care monitoring may have different effects than a more general approach. We therefore anticipate some heterogeneity for the primary outcomes and propose to summate all data but also present them separately.
Sensitivity analysis
1. Implication of randomisation We aimed to include trials in a sensitivity analysis if they are described in some way as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when we added the implied randomised studies to those with better description of randomisation, we then employed all data from these studies.
Assumptions for lost binary data
Where assumptions had to be made regarding people lost to follow up (see Dealing with missing data) we compared the findings of the primary outcomes where we used our assumption and compared with completer data only. If there was a substantial difference, we reported results and discussed them but continue to employ our assumption.
R E S U L T S
Description of studies
See: Characteristics of excluded studies; Characteristics of studies awaiting classification.
Results of the search
The initial search of the Cochrane Schizophrenia Group's register of trials in 2009 was a combined search designed to identify studies which would be relevant to this review, and to another sister review on physical health advice for people with serious mental illness (Tosh 2010). The search identified 2382 references (from 1558 studies). After examining the reports, only three were suitable for further examination and all were excluded. Despite the fact that the Cochrane Schizophrenia Group's register of trials is compiled from large comprehensive and systematic searches for trials, we undertook unsystematic searches of a sample of the component databases (BNI, CINHAL, EMBASE, MEDLINE and PsychINFO) to determine if any material may have been overlooked. We searched using specific phrases ('physical health', 'monitoring' and 'mental illness') as the searches that create the Cochrane Schizophrenia Group's register of trials are methodology specific. We did not identify any further relevant trials.
Included studies
No studies met the criteria for this review.
Excluded studies
One trial was excluded, on the basis that it is an ongoing trial in the recruitment stage which is focusing on the monitoring of mental health parameters and not physical health (Jürgens 2008). Another was excluded as it monitored the effects of a pharmacological intervention on a physical health parameter (Lan 2007). The third exclusion was on the basis that the trial compared the effects of different ways of monitoring a specific anxiety symptom, and did not look at a physical health (Rostow 1980) . For details please see Characteristics of excluded studies. 1. Awaiting assessment Sixty one studies are awaiting assessment.
Ongoing studies
We are not aware of any ongoing studies.
Risk of bias in included studies
There were no studies that fulfilled the criteria for inclusion. We did not exclude any studies on the grounds of poor methodology.
Allocation
Blinding
Incomplete outcome data
Selective reporting
Other potential sources of bias
Effects of interventions
Currently we know of no randomised studies describing the effects of monitoring physical health care of people with serious mental illnesses.
D I S C U S S I O N
Summary of main results
1. No trial-based evidence Current medical practice in the UK is led by guidance from bodies such as the National Institute of Clinical Excellence (NICE 2006) and The Maudsley Prescribing Guidelines (Taylor 2009) who predominantly base their guidance on little more than anecdotal evidence, consensus of opinion (Marder 2004) and good intentions. The association between schizophrenia and poor physical health is well established (Robson 2007) and, taken at face value, current guidance seems to make sense. Unfortunately history is littered with treatments and policies which 'seemed like a good idea at the time' but which, with the benefit of hindsight, were, at best, ineffective and, at worst, resulted in harm. Extreme examples of well-intentioned treatments could be trepanation for epilepsy (Adams 1856), ice-pick lobotomies for unruly children (El-Hai 2008) , or radium water for high blood pressure (JAMA 1925) . More contemporary and more subtle is the wide use of oil of evening primrose oil for many ailments when evidence for efficacy is poor (Bayles 2009). This could mean that hopes are raised inappropriately, and, perhaps other more effective treatments avoided. When it comes to mental health policy, the early legislation for the Care Programme Approach in the UK was well intentioned but ultimately imported a largely wasteful and ineffective package of care from the US (Marshall 1996, Marshall 1998) at a time when even those in the US had found it necessary to substantially evolve the approach into a more effective package (Assertive Outreach). In more recent times the evidence to support the view that specialist mental health services such as Dual Diagnosis Teams, Early Intervention or Assertive Outreach Teams are more beneficial than appropriately supported Community Mental Health Teams is not as strong as would have been originally thought (Ley 2000). Care, and the time of people with serious mental illness is too costly to waste on ideas that are not of proven benefit. Vulnerable people with serious mental illness should surely expect that all aspects of their care has been subject to some degree of evaluation.
Overall completeness and applicability of evidence
Quality of the evidence
The three studies we obtained for closer inspection were not excluded because of issues of quality. We were just unable to find any studies that were vaguely relevant, regardless of whether they were high or poor quality.
Potential biases in the review process
The search criteria both on the Cochrane Schizophrenia Group Trials Register (October 2009) and on our unsystematic search (see: Searching other resources) should have been robust enough to detect relevant studies. It is possible, however, that we have failed to identify small studies but we think it unlikely that we would have missed large trials. Studies published in languages other than English, and those with equivocal results, are often difficult to find (Egger 1997) . Our search was biased by use of English phrases. However, given that the Cochrane Schizophrenia Group's Register covers many languages but is indexed in English we feel that this would not have missed many studies within the register. For example, the search uncovered 101 studies for which the title was only available in Chinese characters. These were checked for relevance by a Chinese speaking colleague (Jun Xia) and none were identified as possibly relevant to this review.
Agreements and disagreements with other studies or reviews
The only other similar systematic review that we are aware of is Bradshaw 2005. This reports on efficacy of healthy living interventions for people with schizophrenia. They too identified no trials of monitoring. We agree with Bradshaw 2005 that rigorous studies are needed.
A U T H O R S ' C O N C L U S I O N S Implications for practice
For people with schizophrenia
Due to the lack of evidence for the current guidance based physical health monitoring it is important that people with schizophrenia expect clinicians to explain their intentions clearly. It would seem reasonable that people with schizophrenia are given the choice of whether they want to be monitored in this way or, whether they would want to add to the body of evidence, one way or another, by being part of a well designed trial from which outcomes relevant to their care would be derived.
For clinicians
Clinicians should be aware that current guidance on monitoring the physical health for people with serious mental illness is not supported by any evidence from randomised controlled trials. It would seem reasonable that this is explained to people with serious mental illness. It is possible clinicians are expending much effort, time and financial expenditure on monitoring the physical health of people with serious mental illnesses which is unnecessary, intrusive and costly. Clinicians should, therefore, take a much more critical view of current guidance and attempt to initiate or get involved with any studies which could provide an evidence-base for this practice.
For policy makers or managers
Current policies and guidelines are born out of good intentions and "the evidence for such interventions remains uncertain" (NICE 2006) . This puts policy makers in a difficult position galvanising consensus rather than evidence. There remains an enduring concern that "L'enfer est plein de bonnes volontés ou désirs" [Hell is full of good intentions or wishes] (St. Bernard of Clairvaux 1150 quoted in Ammer 2003). Policy makers or managers should be better at recommending active research interest in this area. 4. Note: the 61 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
Implications for research
General
We could not identify any randomised trials that assessed the effectiveness of physical health monitoring in people with serious mental illness which contradicted the view that current guidance and practice is based on good intentions and expert opinion. Basing care on solely evidence from trials is not realistic (Tanenbaum 2005 and Cooper 2003) , however, many treatments or approaches that are not well-evaluated are given to people, when it is actually entirely possible to evaluate these approaches. Health care professionals may be doing far more good than they realise -or far more harm. As part of a duty of care, we argue, that 'what could be known, should be known'.
Specific
We realise that much thought and care goes into the design of randomised studies. We have, however, also given this issue some consideration and suggest what we think to be a feasible design see Additional tables (Table 1) .
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Characteristics of studies awaiting assessment [ordered by study ID]
AstraZeneca 2006
Methods
Participants
Interventions
Outcomes
Notes
To be assessed. 
Baptista 2010
Methods
Participants
Baptista 2010 (Continued)
Notes
To be assessed.
Becker 2005
Methods
Participants
Interventions
Outcomes Notes To be assessed.
Bobo 2011
Methods
Participants
Interventions
Bushe 2010
Methods
Participants
Interventions
Byerly 2010
Methods
Participants
Interventions
Outcomes Byerly 2010 (Continued)
Notes
Carmeli 2012
Methods
Participants
Interventions
ChiCTR-TRC-12002273
Methods
Participants
Interventions
Cordes 2011
Methods
Participants
Interventions
Fernandez 2010
Methods
Participants
Interventions
Outcomes 
Fernandez 2010 (Continued)
Notes
Henderson 2011
Methods
Participants
Interventions
IRCT201107187049N1
Methods
Participants
Interventions
ISRCTN63382258
Methods
Participants
Interventions
Kent 2011
Methods
Participants
Interventions
Outcomes Kent 2011 (Continued)
Notes
Kluge 2012
Methods
Participants
Interventions
Outcomes Notes
Krakowski 2011
Methods
Participants
Interventions
Kreyenbuhl 2011
Methods
Participants
Interventions
Outcomes Notes To be assessed. 
L'Italien 2006
Methods
Participants
L'Italien 2006 (Continued)
Notes
Lencz 2010
Methods
Participants
Interventions
Lieberman 2010
Methods
Participants
Interventions
Loza 2011
Methods
Participants
Interventions
Miceli 2010
Methods
Participants
Interventions
Outcomes Miceli 2010 (Continued)
Notes
NCT00418171
Methods
Participants
Interventions
NCT00484302
Methods
Participants
Interventions
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D A T A A N D A N A L Y S E S
This review has no analyses. Table 1 . Suggested design of study
A D D I T I O N A L T A B L E S
Methods
Allocation: randomised, clearly described. Blinding: single -particular to specific outcomes (see below). Duration: 6 months.
